Marker Therapeutics Inc (MRKR)

[hanscott]

Oh, and another good thing in Arm A is that of the six patients in the trial long enough to hit the Progression Free Survival (PFS) mark only one of the six has seen disease progression. And as Poods noted, for a PIIb/PIII we would likely have to use Median OS as an endpoint, but it's possible we could use the surrogates PFS or even Overall Response Rates (ORR). The fact that our treatment is nontoxic might make it possible for us to use the later, which would take less time for the study and might be easier endpoints to reach.